JP2014503537A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503537A5
JP2014503537A5 JP2013545218A JP2013545218A JP2014503537A5 JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5 JP 2013545218 A JP2013545218 A JP 2013545218A JP 2013545218 A JP2013545218 A JP 2013545218A JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5
Authority
JP
Japan
Prior art keywords
cancer
breast cancer
positive
treatment
body according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545218A
Other languages
English (en)
Japanese (ja)
Other versions
JP5886873B2 (ja
JP2014503537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/073041 external-priority patent/WO2012084711A1/en
Publication of JP2014503537A publication Critical patent/JP2014503537A/ja
Publication of JP2014503537A5 publication Critical patent/JP2014503537A5/ja
Application granted granted Critical
Publication of JP5886873B2 publication Critical patent/JP5886873B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013545218A 2010-12-24 2011-12-16 Ｎ置換アゼチジン誘導体 Expired - Fee Related JP5886873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10196960 2010-12-24
EP10196960.8 2010-12-24
PCT/EP2011/073041 WO2012084711A1 (en) 2010-12-24 2011-12-16 N-substituted azetidine derivatives

Publications (3)

Publication Number Publication Date
JP2014503537A JP2014503537A (ja) 2014-02-13
JP2014503537A5 true JP2014503537A5 (https=) 2014-08-21
JP5886873B2 JP5886873B2 (ja) 2016-03-16

Family

ID=43778253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545218A Expired - Fee Related JP5886873B2 (ja) 2010-12-24 2011-12-16 Ｎ置換アゼチジン誘導体

Country Status (7)

Country Link
US (1) US9540361B2 (https=)
EP (1) EP2655367B1 (https=)
JP (1) JP5886873B2 (https=)
AU (1) AU2011347718B2 (https=)
CA (1) CA2819299A1 (https=)
ES (1) ES2586908T3 (https=)
WO (1) WO2012084711A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016174551A1 (en) * 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
KR20240142622A (ko) * 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
HK1258851A1 (zh) 2015-11-09 2019-11-22 豪夫迈‧罗氏有限公司 四氢萘雌激素受体调节剂及其用途
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
EA034994B1 (ru) * 2016-02-15 2020-04-15 Санофи 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EP3640251B1 (en) * 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
ES3039455T3 (en) 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112041307B (zh) 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
CR20200621A (es) 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
KR20220119415A (ko) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
CA3169679A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
CN113248455A (zh) * 2021-05-25 2021-08-13 湖北科技学院 一种3,5-二取代异噁唑类衍生物及其合成方法
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
WO2023059714A1 (en) * 2021-10-06 2023-04-13 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
CN117924262A (zh) * 2022-10-14 2024-04-26 中国科学院上海药物研究所 二氢苯并噻喃类衍生物及其制备方法和用途
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
EP4611901A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
CN116813603B (zh) * 2023-06-02 2024-10-22 成都市第三人民医院 一种选择性雌激素受体α降解化合物及其制备方法和应用
EP4735452A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
TW200304371A (en) * 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
US20030225132A1 (en) 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
DK1501819T3 (da) 2002-04-24 2011-01-10 Merck Sharp & Dohme Østrogenreceptormodulatorer
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation

Similar Documents

Publication Publication Date Title
JP2014503537A5 (https=)
JP2017523247A5 (https=)
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
GT201500206A (es) Modulador del receptor de andrógeno y usos de este
IL208844A0 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc
MX367624B (es) Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática.
IL252766A0 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
WO2015104373A3 (en) Duocarmycin adcs for use in treatment of endometrial cancer
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
CA3277615A1 (en) Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
MX2013006140A (es) Uso de ligandos sigma en dolor por cancer de huesos.
NI201200071A (es) Nuevo uso antitumoral de cabazitaxel
WO2014152451A3 (en) Compositions and methods for controlled localized delivery of bone forming therapeutic agents
NZ626736A (en) Phragamalin limonoids for the treatment of sexual dysfunction
PH12012501812A1 (en) Compositions and methods for non-toxic delivery of antiprogestins
Boisen et al. Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges
SG11202000881VA (en) Adjuvant therapy for use in prostate cancer treatment
NZ742470A (en) Combination therapy for cancer
UA29848U (uk) Застосування системної реконструктивної терапії як способу лікування мігрені
SI3643707T1 (sl) Spojina, označena z 18F, za diagnozo raka prostate in njena uporaba
RU2009123421A (ru) Способ применения наноформы транс-резвератрола для лечения и профилактики гормонозависимых пролиферативных процессов, в том числе опухолей